<![CDATA[Daraxonrasib Yields Activity in Previously Treated RAS-Mutant NSCLC]]>

Phase 1positivedaraxonrasibPositive

AI Analysis

Summary

Daraxonrasib demonstrated objective response rates exceeding 30% in a phase 1/2 study of previously treated patients with RAS-mutant non-small cell lung cancer.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

Objective responses in more than 30% of patients with previously treated RAS-mutant NSCLC

Importance:5/10

Sentiment:

0.70

oncologyNSCLCRAS-mutantphase 1/2clinical trial

Read the original article

Published by Cancer Network on September 9, 2026 2:00 PM

Read Original